Enoxaparin-Lekhim
General properties
Antithrombotic agents. Heparin group.
The medicinal product is indicated for use in adults:
– For the prevention of venous thromboembolic complications in surgical patients at moderate to high risk, especially in patients undergoing orthopedic or general surgical interventions, including surgical interventions for oncological diseases.
– For the prevention of venous thromboembolic complications in therapeutic patients with acute diseases (such as acute heart failure, respiratory failure, severe infections or rheumatic diseases) and reduced mobility with the increased risk of venous thromboembolism.
– For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), except for the cases of PE, which may require thrombolytic therapy or surgery.
– For the long-term treatment of DVT and PE and the prevention of their recurrence in patients with active cancer.
– For the prevention of thrombus formation in the extracorporeal circulation during hemodialysis.
– in acute coronary syndrome:
– for the treatment of unstable stenocardia and non-ST segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid;
– for the treatment of acute ST-segment elevation myocardial infarction (STEMI), particularly in patients who are scheduled for medical treatment or subsequent percutaneous coronary intervention (PCI).
Enoxaparin sodium is contraindicated in patients with:
- Hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low molecular weight heparins, or to any of the excipients (see section "Composition").
- History of immune-mediated heparin-induced thrombocytopenia (HIT) within the last 100 days or presence of circulating antibodies (see also section "Special warnings and precautions for use").
– Active clinically significant bleeding and conditions with a high risk of bleeding, including recent hemorrhagic stroke, gastrointestinal ulcer, presence of a malignant neoplasm with a high risk of bleeding, recent surgery on the brain, spinal cord or eyes, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or serious intraspinal or intracerebral vascular anomalies;
– Spinal or epidural anesthesia or locoregional anesthesia, if enoxaparin sodium has been used for treatment within the previous 24 hours (see section "Special instructions").
Pharmaceutical characteristics
Transparent, colorless or slightly yellowish solution.
Keep out of reach of children. Store in original packaging at a temperature not exceeding 25 °C. Do not freeze.
